Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Questcor HP Acthar

Executive Summary

Questcor plans to ship HP Acthar gel in September following acquisition of the andrenocorticotropic hormone gel from Aventis. The National Organization for Rare Disorders has administered a patient access program for Acthar since 1996 due to limited availability of the product; Questcor expects to resume normal distribution of Acthar in the fall. Aventis will continue to manufacture Acthar for two to three years while production is transitioned to a new manufacturer. Acthar is approved for acute exacerbations of multiple sclerosis but is commonly used off-label to treat infantile spasms. Questcor will use its 19-rep sales force to promote Acthar to the approximately 900 pediatric neurologists in the U.S
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS038317

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel